Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

PN-101

Biologic

PPaean Biotechnology Inc.

PN-101 is one of 44 biologic programs targeting Dermatomyositis. It is currently in development.

1

Indications

2

Total Trials

1

Active Trials

43

Competitors

Pipeline

Status by Indication[3][1]

Indication

DermatomyositisActive, not recruiting

DermatomyositisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

49 competitors in Dermatomyositis

#DrugCompanyPhaseTrials

Xeljanz

PPrism Pharmaceuticals

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Olumiant

Stelara

Johnson & Johnson

JAK Inhibitor

FFred Hutchinson Cancer Center

Proleukin

IIovance Biotherapeutics, Inc.

Otezla

Actemra

Ultomiris

Jakafi

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Dermatomyositis

NCT07122648

Clinical

Trials by Indication[1]

Dermatomyositis2 trials

Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis

Not yet recruiting·PPaean Biotechnology Inc.·Phase 2·NCT07122648·36 enrolled

Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis

Completed·PPaean Biotechnology Inc.·Phase 1/2·NCT04976140·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PN-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PN-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PN-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Paean Biotechnology Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: PPaean Biotechnology Inc.

Related News